A pivotal clinical trial assessing new three-monthly formulation of letrozole in comparison with the daily administration of oral doses of Femara® 2.5 mg
Latest Information Update: 09 Apr 2025
At a glance
- Drugs Letrozole (Primary)
- Indications Breast cancer
- Focus Pharmacokinetics; Registrational
Most Recent Events
- 25 Mar 2025 According to ROVI media release, e company plans to commence the phase III clinical development of Letrozole SIE, two products based on ISM technology that will expand the portfolio of products developed internally, in the fourth quarter of 2025.
- 08 May 2023 New trial record